rs1057519424
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_007198.4(PLPBP):c.320-2A>G variant causes a splice acceptor, intron change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000805 in 1,614,076 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_007198.4 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PLPBP | NM_007198.4 | c.320-2A>G | splice_acceptor_variant, intron_variant | ENST00000328195.8 | NP_009129.1 | |||
PLPBP | NM_001349346.2 | c.320-2A>G | splice_acceptor_variant, intron_variant | NP_001336275.1 | ||||
PLPBP | NM_001349347.2 | c.314-2A>G | splice_acceptor_variant, intron_variant | NP_001336276.1 | ||||
PLPBP | NM_001349348.2 | c.164-2A>G | splice_acceptor_variant, intron_variant | NP_001336277.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PLPBP | ENST00000328195.8 | c.320-2A>G | splice_acceptor_variant, intron_variant | 1 | NM_007198.4 | ENSP00000333551.3 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152236Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000398 AC: 1AN: 251450Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135906
GnomAD4 exome AF: 0.00000752 AC: 11AN: 1461840Hom.: 0 Cov.: 31 AF XY: 0.00000688 AC XY: 5AN XY: 727212
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152236Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 74390
ClinVar
Submissions by phenotype
Epilepsy, early-onset, vitamin B6-dependent Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego | Jan 16, 2020 | This variant abolishes the canonical splice acceptor site of intron 4 and is therefore predicted to lead to abnormal splicing. This variant has been previously reported as a compound heterozygous change with a second canonical splice site variant, c.207+1G>A, in a patient with Epilepsy, early-onset, vitamin B6-dependent (PMID: 27912044). Analysis of cDNA generated from RNA extracted from fibroblasts of the previously described patient showed that c.320-2A>G and c.207+1G>A affect DNA splicing and result in decreased mRNA expression. In addition, western blot analysis showed minimally detectable PROSC protein (PMID: 27912044). The c.320-2A>G variant is present in the heterozygous state in the gnomAD population database at a frequency of 0.0007% (2/282858) and is absent in the homozygous state, thus is presumed to be rare. Multiple splice prediction tools suggest this variant is likely to interfere with normal splicing. Based on the available evidence, the c.320-2A>G variant is classified as Pathogenic. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Aug 14, 2023 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 19, 2022 | This variant is present in population databases (no rsID available, gnomAD 0.002%). For these reasons, this variant has been classified as Pathogenic. Studies have shown that disruption of this splice site is associated with altered splicing resulting in unknown protein product impact (PMID: 27912044). ClinVar contains an entry for this variant (Variation ID: 374855). Disruption of this splice site has been observed in individual(s) with pyridoxine-dependent epilepsy (PMID: 27912044, 33766999). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This sequence change affects an acceptor splice site in intron 4 of the PROSC gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in PROSC are known to be pathogenic (PMID: 27912044). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at